Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Neuroblastoma to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Neuroblastoma to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Neuroblastoma 30
Apr 19, 2016: Kolltan Pharmaceuticals Announces Presentation of Preclinical Data for an Anti-ALK Monoclonal Antibody-Drug Conjugate (ADC) in Neuroblastoma Models at the 2016 American Association for Cancer Research (AACR) Annual Meeting 30
Clinical Trial Profile Snapshots 31
Appendix 352
Abbreviations 352
Definitions 352
Research Methodology 353
Secondary Research 353
About GlobalData 354
Contact Us 354
Disclaimer 354
Source 355
List of Tables
Neuroblastoma Therapeutics, Global, Clinical Trials by Region, 2016* 6
Neuroblastoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Neuroblastoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Neuroblastoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Neuroblastoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Neuroblastoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Neuroblastoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Neuroblastoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Neuroblastoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Neuroblastoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Neuroblastoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Neuroblastoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Neuroblastoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Neuroblastoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Neuroblastoma Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Neuroblastoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Neuroblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Neuroblastoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Neuroblastoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Neuroblastoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Neuroblastoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Neuroblastoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Neuroblastoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
List of Figures
Neuroblastoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Neuroblastoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Neuroblastoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Neuroblastoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Neuroblastoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Neuroblastoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Neuroblastoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Neuroblastoma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Neuroblastoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Neuroblastoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Neuroblastoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Neuroblastoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Neuroblastoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Neuroblastoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Neuroblastoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Neuroblastoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Neuroblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Neuroblastoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Neuroblastoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Neuroblastoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Neuroblastoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Neuroblastoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Neuroblastoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 353